Abvc BiopharmaABVC
13F holders, Q4 2025 (December 31)At the end of Q4 2025, 14 institutions reported holding Abvc Biopharma Inc. (ABVC) in their 13F filings, unchanged from Q3 2025. 2 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($613K), Geode Capital Management, LLC ($431K) and Renaissance Technologies ($243K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Abvc Biopharma Inc.
- CUSIP
- 00091F304
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $34K |
| Exits | 2 | $60K |
All 13F filers, Q3 2025 → Q4 2025: 103,781 shares bought and 34,205 shares sold, net +69,576 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Vanguard Group Inc. | 0.00% | Add +7.7% | 287,937 | $613K |
| Geode Capital Management, LLC | 0.00% | Add +7.8% | 202,365 | $431K |
| Renaissance Technologies | 0.00% | Add +3.4% | 114,263 | $243K |
| State Street Corp. | 0.00% | No change | 72,800 | $155K |
| BlackRock, Inc. | 0.00% | No change | 56,442 | $120K |
| Citadel Advisors | 0.00% | Add +254.6% | 55,543 | $118K |
| Northern Trust Corp. | 0.00% | Add +29.3% | 32,087 | $68K |
| XTX Topco Ltd | 0.00% | Reduce -54.6% | 11,261 | $24K |
| Jane Street Group, LLC | 0.00% | New | 10,867 | $23K |
| Morgan Stanley | 0.00% | New | 5,175 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +48.2% | 3,193 | $7K |
| UBS Group AG | 0.00% | Add +40.0% | 2,588 | $6K |
| Simplex Trading, LLC | 0.00% | Reduce -82.3% | 196 | $417 |
| Bank of America Corp. | 0.00% | Add +8.0% | 189 | $402 |
"% of holder's portfolio" is ABVC's weight in each manager's 13F, not the share of Abvc Biopharma Inc. the manager owns.